Literature DB >> 5015292

Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens.

M G Dahl, M M Gregory, P J Scheuer.   

Abstract

Liver histological appearances were studied in 44 patients treated for psoriasis with methotrexate. Cirrhosis was found in six and hepatic fibrosis in another 11. Of these 17 patients 12 had received methotrexate by a regimen of frequent small dosage, two had been treated by a regimen of intermittent large dosage, while three had been treated at different times by both methods. The prevalence of cirrhosis and fibrosis was significantly greater in patients treated by frequent small dosage than in those treated by intermittent large dosage, though the dose level (mg/month) was similar in both groups. Hepatic fibrosis, sometimes preceding cirrhosis, seems to develop invariably if treatment with small frequent dosage is sufficiently prolonged. In the few circumstances in which this drug is indicated for psoriasis intermittent large dosage is the treatment regimen of choice.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5015292      PMCID: PMC1787742          DOI: 10.1136/bmj.1.5801.654

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  17 in total

1.  Parenteral methotrexate for psoriasis.

Authors:  C J McDonald; J Bertino
Journal:  Lancet       Date:  1968-04-20       Impact factor: 79.321

2.  Cirrhosis following methotrexate administration for psoriasis.

Authors:  E H Epstein; J D Croft
Journal:  Arch Dermatol       Date:  1969-11

3.  Cirrhosis caused by methotrexate in the treatment of psoriasis.

Authors:  S A Muller; G M Farrow; D L Martalock
Journal:  Arch Dermatol       Date:  1969-11

4.  Cirrhosis associated with methotrexate treatment of psoriasis.

Authors:  R O Coe; F E Bull
Journal:  JAMA       Date:  1968-11-11       Impact factor: 56.272

5.  Intermittent high dose oral methotrexate therapy in psoriasis.

Authors:  H Baker
Journal:  Br J Dermatol       Date:  1970-01       Impact factor: 9.302

6.  Liver disease associated with methotrexate treatment of psoriatic patients.

Authors:  H V Dubin; E R Harrell
Journal:  Arch Dermatol       Date:  1970-11

7.  Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis.

Authors:  G D Weinstein; J W Cox; D W Suringa; M M Millard; M Kalser; P Frost
Journal:  Arch Dermatol       Date:  1970-12

8.  Methotrexate liver toxicity.

Authors:  H Sharp; M Nesbit; J White; W Krivit
Journal:  J Pediatr       Date:  1969-05       Impact factor: 4.406

9.  Hepatotoxic effects of methotrexate.

Authors:  E M Hersh; V G Wong; E S Henderson; E J Freireich
Journal:  Cancer       Date:  1966-04       Impact factor: 6.860

10.  Methotrexate for psoriasis.

Authors:  R B Rees; J H Bennett; H I Maibach; H L Arnold
Journal:  Arch Dermatol       Date:  1967-01
View more
  23 in total

1.  Hepatic methotrexate content and progression of hepatic fibrosis: preliminary findings.

Authors:  M J Ahern; S Kevat; W Hill; P J Hayball; H Harley; P D Hall
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

Review 2.  Guidelines for management of patients with psoriasis. Workshop of the Research Unit of the Royal College of Physicians of London; Department of Dermatology, University of Glasgow; British Association of Dermatologists.

Authors: 
Journal:  BMJ       Date:  1991-10-05

Review 3.  Long-term effects on the liver.

Authors:  P J Scheuer
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1975

Review 4.  [Methotrexate].

Authors:  R Rau
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

5.  Methotrexate therapy in rheumatoid arthritis. Current status.

Authors:  W S Wilke; A H Mackenzie
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of methotrexate.

Authors:  D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

7.  Oral methotrexate.

Authors:  J R Taylor; K M Halprin; E R Schiff
Journal:  Dig Dis Sci       Date:  1986-04       Impact factor: 3.199

8.  Liver disease after bone marrow transplantation.

Authors:  M J Farthing; M L Clark; J P Sloane; R L Powles; T J McElwain
Journal:  Gut       Date:  1982-06       Impact factor: 23.059

9.  The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis.

Authors:  P Seideman; O Beck; S Eksborg; M Wennberg
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

Review 10.  Drug-induced liver disease.

Authors:  H J Zimmerman
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.